Cargando…

Modelling Predictors of Molecular Response to Frontline Imatinib for Patients with Chronic Myeloid Leukaemia

BACKGROUND: Treatment of patients with chronic myeloid leukaemia (CML) has become increasingly difficult in recent years due to the variety of treatment options available and challenge deciding on the most appropriate treatment strategy for an individual patient. To facilitate the treatment strategy...

Descripción completa

Detalles Bibliográficos
Autores principales: Banjar, Haneen, Ranasinghe, Damith, Brown, Fred, Adelson, David, Kroger, Trent, Leclercq, Tamara, White, Deborah, Hughes, Timothy, Chaudhri, Naeem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5207707/
https://www.ncbi.nlm.nih.gov/pubmed/28045960
http://dx.doi.org/10.1371/journal.pone.0168947
_version_ 1782490417951932416
author Banjar, Haneen
Ranasinghe, Damith
Brown, Fred
Adelson, David
Kroger, Trent
Leclercq, Tamara
White, Deborah
Hughes, Timothy
Chaudhri, Naeem
author_facet Banjar, Haneen
Ranasinghe, Damith
Brown, Fred
Adelson, David
Kroger, Trent
Leclercq, Tamara
White, Deborah
Hughes, Timothy
Chaudhri, Naeem
author_sort Banjar, Haneen
collection PubMed
description BACKGROUND: Treatment of patients with chronic myeloid leukaemia (CML) has become increasingly difficult in recent years due to the variety of treatment options available and challenge deciding on the most appropriate treatment strategy for an individual patient. To facilitate the treatment strategy decision, disease assessment should involve molecular response to initial treatment for an individual patient. Patients predicted not to achieve major molecular response (MMR) at 24 months to frontline imatinib may be better treated with alternative frontline therapies, such as nilotinib or dasatinib. The aims of this study were to i) understand the clinical prediction ‘rules’ for predicting MMR at 24 months for CML patients treated with imatinib using clinical, molecular, and cell count observations (predictive factors collected at diagnosis and categorised based on available knowledge) and ii) develop a predictive model for CML treatment management. This predictive model was developed, based on CML patients undergoing imatinib therapy enrolled in the TIDEL II clinical trial with an experimentally identified achieving MMR group and non-achieving MMR group, by addressing the challenge as a machine learning problem. The recommended model was validated externally using an independent data set from King Faisal Specialist Hospital and Research Centre, Saudi Arabia. PRINCIPLE FINDINGS: The common prognostic scores yielded similar sensitivity performance in testing and validation datasets and are therefore good predictors of the positive group. The G-mean and F-score values in our models outperformed the common prognostic scores in testing and validation datasets and are therefore good predictors for both the positive and negative groups. Furthermore, a high PPV above 65% indicated that our models are appropriate for making decisions at diagnosis and pre-therapy. Study limitations include that prior knowledge may change based on varying expert opinions; hence, representing the category boundaries of each predictive factor could dramatically change performance of the models.
format Online
Article
Text
id pubmed-5207707
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-52077072017-01-19 Modelling Predictors of Molecular Response to Frontline Imatinib for Patients with Chronic Myeloid Leukaemia Banjar, Haneen Ranasinghe, Damith Brown, Fred Adelson, David Kroger, Trent Leclercq, Tamara White, Deborah Hughes, Timothy Chaudhri, Naeem PLoS One Research Article BACKGROUND: Treatment of patients with chronic myeloid leukaemia (CML) has become increasingly difficult in recent years due to the variety of treatment options available and challenge deciding on the most appropriate treatment strategy for an individual patient. To facilitate the treatment strategy decision, disease assessment should involve molecular response to initial treatment for an individual patient. Patients predicted not to achieve major molecular response (MMR) at 24 months to frontline imatinib may be better treated with alternative frontline therapies, such as nilotinib or dasatinib. The aims of this study were to i) understand the clinical prediction ‘rules’ for predicting MMR at 24 months for CML patients treated with imatinib using clinical, molecular, and cell count observations (predictive factors collected at diagnosis and categorised based on available knowledge) and ii) develop a predictive model for CML treatment management. This predictive model was developed, based on CML patients undergoing imatinib therapy enrolled in the TIDEL II clinical trial with an experimentally identified achieving MMR group and non-achieving MMR group, by addressing the challenge as a machine learning problem. The recommended model was validated externally using an independent data set from King Faisal Specialist Hospital and Research Centre, Saudi Arabia. PRINCIPLE FINDINGS: The common prognostic scores yielded similar sensitivity performance in testing and validation datasets and are therefore good predictors of the positive group. The G-mean and F-score values in our models outperformed the common prognostic scores in testing and validation datasets and are therefore good predictors for both the positive and negative groups. Furthermore, a high PPV above 65% indicated that our models are appropriate for making decisions at diagnosis and pre-therapy. Study limitations include that prior knowledge may change based on varying expert opinions; hence, representing the category boundaries of each predictive factor could dramatically change performance of the models. Public Library of Science 2017-01-03 /pmc/articles/PMC5207707/ /pubmed/28045960 http://dx.doi.org/10.1371/journal.pone.0168947 Text en © 2017 Banjar et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Banjar, Haneen
Ranasinghe, Damith
Brown, Fred
Adelson, David
Kroger, Trent
Leclercq, Tamara
White, Deborah
Hughes, Timothy
Chaudhri, Naeem
Modelling Predictors of Molecular Response to Frontline Imatinib for Patients with Chronic Myeloid Leukaemia
title Modelling Predictors of Molecular Response to Frontline Imatinib for Patients with Chronic Myeloid Leukaemia
title_full Modelling Predictors of Molecular Response to Frontline Imatinib for Patients with Chronic Myeloid Leukaemia
title_fullStr Modelling Predictors of Molecular Response to Frontline Imatinib for Patients with Chronic Myeloid Leukaemia
title_full_unstemmed Modelling Predictors of Molecular Response to Frontline Imatinib for Patients with Chronic Myeloid Leukaemia
title_short Modelling Predictors of Molecular Response to Frontline Imatinib for Patients with Chronic Myeloid Leukaemia
title_sort modelling predictors of molecular response to frontline imatinib for patients with chronic myeloid leukaemia
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5207707/
https://www.ncbi.nlm.nih.gov/pubmed/28045960
http://dx.doi.org/10.1371/journal.pone.0168947
work_keys_str_mv AT banjarhaneen modellingpredictorsofmolecularresponsetofrontlineimatinibforpatientswithchronicmyeloidleukaemia
AT ranasinghedamith modellingpredictorsofmolecularresponsetofrontlineimatinibforpatientswithchronicmyeloidleukaemia
AT brownfred modellingpredictorsofmolecularresponsetofrontlineimatinibforpatientswithchronicmyeloidleukaemia
AT adelsondavid modellingpredictorsofmolecularresponsetofrontlineimatinibforpatientswithchronicmyeloidleukaemia
AT krogertrent modellingpredictorsofmolecularresponsetofrontlineimatinibforpatientswithchronicmyeloidleukaemia
AT leclercqtamara modellingpredictorsofmolecularresponsetofrontlineimatinibforpatientswithchronicmyeloidleukaemia
AT whitedeborah modellingpredictorsofmolecularresponsetofrontlineimatinibforpatientswithchronicmyeloidleukaemia
AT hughestimothy modellingpredictorsofmolecularresponsetofrontlineimatinibforpatientswithchronicmyeloidleukaemia
AT chaudhrinaeem modellingpredictorsofmolecularresponsetofrontlineimatinibforpatientswithchronicmyeloidleukaemia